Chimeric Antigen Receptor T-Cell Therapy of Neurolymphomatosis Monitored by FDG PET/CT

Siqi Li1, Hongrong Wang2, Guanyun Wang1

  • 1From the Department of Nuclear Medicine, Beijing Friendship Hospital of Capital Medical University, Beijing, China.

Clinical Nuclear Medicine
|January 30, 2023
PubMed

18 F-FDG PET/CT was performed to evaluate possible recurrent B-cell lymphoblastic lymphoma in a 34-year-old man. The images showed multiple foci of increased activity in the nerve root and peripheral nerve. A biopsy confirmed the diagnosis of neurolymphomatosis. After receiving chemotherapy, PET/CT showed progressive disease. The patient subsequently received the CD-19 chimeric antigen receptor T-cell therapy. A follow-up PET/CT acquired 30 days after chimeric antigen receptor T-cell therapy revealed no abnormal FDG activity.

Related Concept Videos